Chemomab Therapeutics

Company Overview

Snapshot

Founded in November 2011 by Adi Mor, Chemomab Therapeutics operates with 11–50 employees. The company has raised $90.5 million across 7 funding rounds from 12 investors. In March 2021, Chemomab Therapeutics completed a reverse merger with Anchiano Therapeutics, leading to its public listing on NASDAQ.

Business overview

Chemomab Therapeutics is a clinical-stage biotechnology company focused on discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet medical needs. The company's core technology centers on CM-101, a first-in-class monoclonal antibody designed to neutralize the soluble protein CCL24, which plays a pivotal role in promoting fibrosis and inflammation. Chemomab serves the healthcare and life sciences sectors, specifically targeting patients with severe and life-threatening fibro-inflammatory conditions, including liver fibrosis in NASH patients and primary sclerosing cholangitis.

Strategic signal

In November 2023, Chemomab Therapeutics received FDA Fast Track Designation for CM-101 for the treatment of Primary Sclerosing Cholangitis. This designation indicates the FDA's recognition of CM-101's potential to address a serious condition and fulfill an unmet medical need, signaling a significant regulatory validation and potentially accelerating its development and review process for investors.

Company Intelligence Q&A

What is Chemomab Therapeutics' primary focus?

Chemomab Therapeutics is a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet medical needs.

When did Chemomab Therapeutics go public?

Chemomab Therapeutics went public on NASDAQ in March 2021, following a reverse merger with Anchiano Therapeutics.

What is CM-101?

CM-101 is Chemomab Therapeutics' first-in-class monoclonal antibody designed to neutralize the soluble protein CCL24, which is implicated in fibrosis and inflammation.

What significant regulatory milestone did Chemomab Therapeutics achieve for CM-101?

In November 2023, Chemomab Therapeutics received FDA Fast Track Designation for CM-101 for the treatment of Primary Sclerosing Cholangitis.

What was the most recent funding event for Chemomab Therapeutics?

In July 2024, Chemomab Therapeutics announced the closing of a private placement, with participation from investors including OrbiMed.